Global Information
회사소개 | 문의

세계의 암 치료제 시장 : 재발 및 전이 부위의 중시

Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions

리서치사 BCC Research
발행일 2018년 12월 상품 코드 762926
페이지 정보 영문 288 Pages
가격
US $ 5,500 ₩ 6,263,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,600 ₩ 7,516,000 PDF by E-mail (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,920 ₩ 9,020,000 PDF by E-mail (Site License)
US $ 9,504 ₩ 10,824,000 PDF by E-mail (Enterprise License)


세계의 암 치료제 시장 : 재발 및 전이 부위의 중시 Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions
발행일 : 2018년 12월 페이지 정보 : 영문 288 Pages

세계의 암 치료제 시장 규모는 2018년 1,281억 달러에서 2023년까지 1,820억 달러로 확대될 것으로 예측되며, 2018-2023년간 7.3%의 연평균 성장률(CAGR)이 전망됩니다.

세계의 암 치료제(Cancer Therapeutics) 시장에 대해 조사했으며, 세계 시장 개요, 국가별 데이터와 분석, 전이·재발을 포함한 암의 발전 단계 설명, 현재의 진단법, 약리학적 접근, 경제적 부담에 관한 정보 및 주요 기업 개요 등을 제공합니다.

제1장 서론

제2장 요약

제3장 암의 생물학

  • 개요
  • 암의 병인
  • 암의 병기
  • 암의 전이

제4장 질환 및 암의 경제적 부담

  • 암의 부담
  • 암 : 발증률 및 유병률 통계 분석
  • 암의 지역적인 패턴

제5장 암의 전이 및 재발에 대한 치료 접근

  • 암의 전이 및 재발에 대한 치료 접근
  • 비제약적 접근
  • 약물 요법
  • 표적형 생물학적 요법
  • 유전자 요법
  • 암혈관 증식을 억제하는 의약품(혈관신생 억제)
  • 맞춤형 암치료(정밀 의료)
  • 주요 암 전이의 치료 선택사항

제6장 암 치료제 : 출시된 제품 및 파이프라인 분석

  • 개요
  • 주요 출시약 프로파일
  • 임상시험
  • 폐암
  • 유방암
  • 전립선암
  • 방광암
  • 위암
  • 기타(간암, 림프종, 백혈병, 난소암, 췌장암)

제7장 규제 및 의료비 상환 상황

  • 미국
  • 캐나다
  • 유럽
  • 일본
  • 중국
  • 인도
  • 한국
  • 브라질
  • 아르헨티나
  • 멕시코
  • 남아프리카공화국
  • 사우디아라비아

제8장 암 치료제 : 세계 및 지역 시장 분석

  • 개요
  • 세계의 암 치료제 시장
  • 북미
  • 유럽
  • 아시아태평양
  • 중앙아메리카 및 라틴아메리카
  • 중동 및 아프리카

제9장 특허 리뷰/신규 개발

제10장 경쟁 상황

제11장 기업 개요

부록 : 두문자어

BBC Research 소개

KSM 19.01.11

List of Tables

  • Summary Table: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 1: Cancer Incidence in the U.S., by Sex, 2017
    • Table 2: Number of Deaths from Cancer in the U.S., by Sex, 2017
    • Table 3: Cancer Treatment Options
    • Table 4: Cancer Drug Treatment Classes
    • Table 5: FDA-Approved Intravenous Therapeutic Monoclonal Antibodies Used to Treat Cancer, 1997-2017
    • Table 6: Approved Tyrosine Kinase Inhibitors (TKIs) Used to Treat Cancer
    • Table 7: Common Chemotherapeutic Agents for Recurrent and Metastatic Breast Cancer
    • Table 8: Drugs Approved for the Treatment of Lung Cancer
    • Table 9: Treatment Options for Stage IV and Recurrent Colon Cancer
    • Table 10: Hormone Therapy for Prostate Cancer
    • Table 11: Drugs Approved for Prostate Cancer
    • Table 12: Drugs Approved for Stomach (Gastric) Cancer
    • Table 13: Drugs Combinations Approved for Stomach (Gastric) Cancer
    • Table 14: Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors
    • Table 15: Drugs Approved for the Treatment of Melanoma
    • Table 16: Drugs Approved for Pancreatic Cancer
    • Table 17: Drugs Approved for Pancreatic Cancer
    • Table 18: Treatment Option Overview for Thyroid Cancer
    • Table 19: Drugs Approved for Thyroid Cancer
    • Table 20: Treatment Option Overview for Endometrial Cancer
    • Table 21: Profiles of Top Marketed Drugs
    • Table 22: Lung Cancer Phase III Clinical Trials, 2018*
    • Table 23: Lung Cancer Phase II Clinical Trials, 2018*
    • Table 24: Lung Cancer Phase I Clinical Trials, 2018*
    • Table 25: Breast Cancer Phase III Clinical Trials, 2018*
    • Table 26: Breast Cancer Phase II Clinical Trials, 2018*
    • Table 27: Breast Cancer Phase I Clinical Trials, 2018*
    • Table 28: Colorectal Cancer Phase III Clinical Trials, 2018*
    • Table 29: Colorectal Cancer Phase II Clinical Trials, 2018*
    • Table 30: Colorectal Cancer Phase I Clinical Trials, 2018*
    • Table 31: Bladder Cancer Phase III Clinical Trials, 2018*
    • Table 32: Bladder Cancer Phase II Clinical Trials, 2018*
    • Table 33: Bladder Cancer Phase I Clinical Trials, 2018*
    • Table 34: Gastric Cancer Phase III Clinical Trials, 2018*
    • Table 35: Gastric Cancer Phase II Clinical Trials, 2018*
    • Table 36: Gastric Cancer Phase I Clinical Trials, 2018*
    • Table 37: Others Phase III Clinical Trials, 2018*
    • Table 38: Others Phase II Clinical Trials, 2018*
    • Table 39: Others Phase I Clinical Trials, 2018*
    • Table 40: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 41: North American Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 42: North American Cancer Therapeutics Market, by Country, Through 2023
    • Table 43: European Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 44: European Cancer Therapeutics Market, by Country, Through 2023
    • Table 45: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 46: Asia-Pacific Cancer Therapeutics Market, by Country, Through 2023
    • Table 47: Central and Latin American Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 48: Central and Latin American Cancer Therapeutics Market, by Country, Through 2023
    • Table 49: Middle East and Africa Cancer Therapeutics Market, by Cancer Type, Through 2023
    • Table 50: Patent Applications Filed on Metastatic Breast Cancer Therapeutics, 2016 - October 2017
    • Table 51: Patent Applications Filed on Metastatic Prostate Cancer Therapeutics, November 2015 - January 2018
    • Table 52: Patent Applications Filed on Metastatic Lung Cancer Therapeutics, August 2015 - January 2018
    • Table 53: Latest Patent Publications Cited Relating to Other Metastatic Cancers, December 2015 - July 2018
    • Table 54: Pfizer Inc.: Patent Expiry Dates for Leading Cancer Drugs
    • Table 55: Merck & Co.: Patent Status of Leading Oncology Products
    • Table 56: Johnson & Johnson: Patent Status of Leading Oncology Products
    • Table 57: F Hoffman-La Roche: Patent Status of Leading Oncology Products
    • Table 58: Sanofi SA: Patent Status of Leading Oncology Products
    • Table 59: AstraZeneca plc: Patent Status of Leading Oncology Products
    • Table 60: Celgene: Patent Status of Leading Oncology Products
    • Table 61: Eli Lilly: Patent Status of Leading Oncology Products
    • Table 62: Recent Industry Developments, December 2017 Through September 2018
    • Table 63: AbbVie, Inc.: Company Financials, by Product, 2015-2017
    • Table 64: Amgen: Company Financials, 2015-2017
    • Table 65: Array Biopharma Inc.: Clinical Stage Drug Portfolio
    • Table 66: AstraZeneca plc.: Company Net Revenue, 2015-2017
    • Table 67: AstraZeneca plc: Company Financials, by Therapeutic Product Group, 2015-2017
    • Table 68: AstraZeneca plc: Company Financials, by Oncology Product Group, 2015-2017
    • Table 69: Bristol-Myers Squibb: Revenue, 2015-2017
    • Table 70: Bristol-Myers Squibb: Oncology Product Sales, 2015-2017
    • Table 71: Celgene Corp.: Company Financials, by Product, 2015-2017
    • Table 72: GlaxoSmithKline: Oncology Product Pipeline
    • Table 73: Gilead Sciences, Inc.: Product Pipeline
    • Table 74: Eli Lilly and Co.: Net Revenue, by Segment, 2015-2017
    • Table 75: Eli Lilly and Co.: Oncology Product Sales, 2015-2017
    • Table 76: F Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2015-2017
    • Table 77: F Hoffman-La Roche Ltd.: Pharmaceutical Division Oncology Product Sales, 2015-2017
    • Table 78: Johnson & Johnson: Company Financials, by Segment, 2015-2017
    • Table 79: Johnson & Johnson: Pharmaceutical Therapeutic Area Product Sales, 2015-2017
    • Table 80: Johnson & Johnson: Oncology Product Sales, 2015-2017
    • Table 81: Merck & Co., Inc.: Therapeutic Area Product Sales, 2015-2017
    • Table 82: Merck & Co., Inc.: Oncology Product Sales, 2015-2017
    • Table 83: Novartis AG: Company Financials, by Business Segment, 2015-2017
    • Table 84: Novartis AG: Major Development Projects
    • Table 85: Pfizer Inc.: Company Financials, 2015-2017
    • Table 86: Pfizer Inc.: Innovative Health (IH) Division Financials, 2015-2017
    • Table 87: Pfizer Inc.: Innovative Health (IH) Division Oncology Product Sales, 2015-2017
    • Table 88: Sanofi SA: Company Financials, 2015-2017
    • Table 89: Sanofi SA: Oncology Product Sales, 2015-2017
    • Table 90: Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer

List of Figures

  • Summary Figure: Global Cancer Therapeutics Market Share, by Cancer Type, 2017
    • Figure 1: Top Selling Oncology Drugs, 2017
    • Figure 2: Distribution of Clinical Trials for Cancer Metastases and Recurrence, by Cancer Type, 2018*
    • Figure 3: Global Cancer Therapeutics Market, 2017-2023
    • Figure 4: Global Cancer Therapeutics Market Share, by Cancer Type, 2017
    • Figure 5: North American Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 6: European Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 7: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 8: Central and Latin American Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 9: Middle East and African Cancer Therapeutics Market, by Cancer Type, 2017-2023
    • Figure 10: Global Cancer Therapeutics Market Share, by Company, 2017

Report Highlights:

The global cancer therapeutics market should grow from $128.1 billion in 2018 to $182.0 billion by 2023 at a compound annual growth rate (CAGR) of 7.3% for the period of 2018-2023.

All other cancers therapeutics market should grow from $39.4 billion in 2018 to reach $55.5 billion by 2023 at a CAGR of 7.1% for the period of 2018-2023.

Lung cancer therapeutics market should grow from $16.7 billion in 2018 to reach $24.6 billion by 2023 at a CAGR of 8.0% for the period of 2018-2023.

Report Scope:

The report on "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions" presents qualitative and quantitative information on the current market dynamics that are influencing the market. It covers a background to cancer, types of cancer, pathogenesis of cancer, and stages of cancer development, including the mechanisms of metastasis and recurrences. It also includes the disease burden through understanding the epidemiology of various cancers. Treatment patterns, which include the pharmacological approaches (covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy, and combinatorial therapy) and non-pharmacological approaches (including surgeries and radiation) are covered to present the various therapeutic options available for the patients. Also included in the report are analyses of key marketed products; the current clinical trial landscape; patent landscape and recent product approvals; regulatory landscape; and reimbursement landscape across different demographics. An overview of the demographics of key regions, namely, North America, Europe, Asia-Pacific, Latin America and the Middle East, with potential growth is also covered. Strategies of global companies engaged in the cancer therapeutic space and the profiles of top companies are also covered.

The quantitative information covered in the report includes -

  • Estimates of the market size of the cancer therapeutics used for treating metastases and recurrence states of cancer. The key cancer types covered include lung cancer, breast cancer, liver cancer, stomach cancer, prostate cancer, colorectal cancer, gastric cancer, cervical cancer, bladder cancer, kidney cancer, ovarian cancer and others. Others includes leukemia, lymphoma, multiple myeloma, brain tumor, thyroid cancer and uteral cancer.
  • Further growth potential and forecast information has been covered for the overall cancer therapeutics market and for segments-cancer types, by region and by country.

Market values provided are based on total revenues of cancer therapeutics drug manufacturers.

As a cancer therapeutics (emphasis on recurrent and metastatic cancer) market report, only pharmacological therapy is covered for computation of the market size. Interventions involving surgeries, radiation, ablations and other medical device interventions are excluded from the market size computation and only qualitative information on the same is covered.

Report Includes:

  • 36 data tables and 55 additional tables
  • An overview of global cancer therapeutics market with special focus on recurrent and metastatic divisions
  • Country specific data and analysis for US, Canada, Mexico, Germany, Italy, U.K, France, China, India, Japan, South Korea, Brazil, Argentina and Chile
  • Description of stages of cancer development including the mechanisms of metastasis and recurrences
  • Insights of current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
  • Snapshot of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries, radiation
  • Complete understanding of causes, risk factors, prevalence and incidence of cancer
  • Information on economic cost burden due to cancer
  • Dossier of recent industry events, product innovation, acquisition, partnership and collaborations and competitor strategies
  • Comprehensive company profiles of major market players of the industry including AbbVie, Inc., Biogen Inc., GlaxoSmithKline plc (GSK), Eli Lilly and Co., Merck & Co., Inc., and Pfizer Inc.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Information Sources
  • Methodology
    • Market Estimation and Forecast
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary

  • Key Findings

Chapter 3: Biology of Cancer

  • Overview
    • Lung Cancer
    • Breast Cancer
    • Melanoma
    • Colorectal Cancer
    • Prostate Cancer
    • Cervical Cancer
  • Pathogenesis of Cancer
    • Genetic Changes
  • Stages of Cancer
    • The TNM Staging System
    • Number Staging Systems
  • Cancer Metastases
    • Routes of Metastasis
    • Drug Resistance
    • Inherent Resistance
    • Acquired Resistance

Chapter 4: Disease and Economic Burden of Cancer

  • Cancer Burden
    • Tobacco Use and Statistics
    • Alcohol Abuse and Cancer Statistics
    • Infectious Diseases and Cancer
    • Inherited Genes/Diseases and Cancer
    • Sun, Ultraviolet Radiation and Cancer
    • Hormones and Cancer
  • Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
    • Incidence and Prevalence Rates for Major Cancer Types
  • Regional Patterns of Cancer
    • Europe
    • North America
    • Asia-Pacific
    • Latin and Central America
    • Middle East and Africa

Chapter 5: Treatment Approaches to Cancer Metastases and Recurrence

  • Treatment Approaches to Cancer Metastases and Recurrence
  • Non-pharmaceutical Approaches
    • Surgery for Cancer
    • Radiotherapy for Cancer
    • Ablation Therapy
  • Pharmacological Therapies
    • Cytotoxic Cancer Chemotherapy
    • Hormone-based Cancer Drugs
  • Targeted Biologic Therapy
    • Monoclonal Antibodies
    • Immune Checkpoint Inhibitors
    • Cancer Growth Blockers
  • Gene Therapy
  • Drugs That Block Cancer Blood Vessel Growth (Antiangiogenics)
  • Personalized Cancer Therapy (Precision Medicine)
  • Treatment Options for Selected Cancer Metastases
    • Breast
    • Bladder Cancer
    • Lung
    • Colorectal Cancer
    • Standard Treatment Options for Stage IV and Recurrent Colon Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Melanoma
    • Kidney Cancer
    • Transitional Cell Cancer (TCC) of the Renal Pelvis and Ureter
    • Pancreatic Cancer
    • Thyroid Cancer
    • Stage I and Stage II Endometrial Cancer
    • Stage III, Stage IV and Recurrent Endometrial Cancer

Chapter 6: Cancer Therapeutics: Marketed Products and Pipeline Analysis

  • Overview
    • Top Selling Oncology Drugs in 2017
  • Profiles of Selected Marketed Drugs
  • Clinical Trials
  • Lung Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trial
  • Breast Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials
  • Colorectal Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials
  • Bladder Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials
  • Gastric Cancer
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials
  • Others (Kidney Cancer, Lymphoma, Leukemia, Ovarian, Pancreatic)
    • Phase III Clinical Trials
    • Phase II Clinical Trials
    • Phase I Clinical Trials

Chapter 7: Regulations and Reimbursement Landscape

  • The United States
  • Canada
  • Europe
    • Mutual Recognition Procedure (MRP)
    • Decentralized Procedure (DCP)
    • Centralized Procedure (CP)
  • Japan
    • Marketing Authorization System
    • Pharmaceutical Reimbursement Approval Process in Japan
  • China
    • Pharmaceutical Regulatory and Legislative Developments in China
  • India
    • Pharmaceutical Regulatory and Legislative Developments in India
  • South Korea
    • Regulatory and Legislative Requirements
    • Pharmaceutical Regulatory and Legislative Developments in South Korea
    • Pharmaceutical Reimbursement Landscape in South Korea
  • Brazil
    • Market Entry and Reimbursement of Pharmaceuticals
  • Argentina
    • Regulatory and Legislative Requirements
  • Mexico
    • Regulation and Regulation Governing Drugs in Mexico
    • Health Insurance Structure in Mexico
  • South Africa
    • Regulatory Requirementsin South Africa
    • Health Insurance Structure in South Africa
    • Reimbursement of Pharmaceuticals in South Africa
  • Saudi Arabia
    • Pharmaceutical Regulatory Requirements in Saudi Arabia
    • Health Insurance Structure in Saudi Arabia

Chapter 8: Cancer Therapeutics: Analysis of Global and Regional Markets

  • Overview
  • Global Cancer Therapeutics Market
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • North America
    • Market Dynamics in North America
    • United States
    • Canada
  • Europe
    • Market Drivers
    • Market Restraints
    • France
    • Germany
    • U.K.
    • Spain
    • Italy
  • Asia-Pacific
    • Market Drivers
    • Market Restraints
    • Japan
    • China
    • India
  • Central and Latin America
    • Market Drivers
    • Market Restraints
    • Brazil
    • Argentina
  • Middle East and Africa
    • Market Drivers
    • Market Restraints

Chapter 9: Patent Review/New Developments

  • Patent Applications by Clinical Application
    • Patent Applications Filed on Metastatic Breast Cancer Therapeutics
    • Patent Applications Filed on Metastatic Prostate Cancer Therapeutics
    • Patent Applications Filed on Metastatic Lung Cancer Therapeutics
    • Patents Applications Filed on Therapeutics for Other Cancer Types
  • Patents and Expiry Dates for Major Products by Leading Suppliers
    • Pfizer Inc.
    • Merck & Co.
    • Johnson & Johnson
    • F Hoffman-La Roche
    • Sanofi SA
    • Novartis AG
    • AbbVie, Inc.
    • AstraZeneca plc
    • Celgene
    • Eli Lilly
    • Gilead Sciences
  • Patents and Expiry Dates for Other Products and Suppliers
    • Targeting Breakpoint Cluster Region-Abelson (BCR-ABL)
    • Targeting Epidermal Growth Factor Receptor (EGFR/ERBB1)
    • Targeting Vascular Endothelial Growth Factor Receptor (VEGFR), PDGFR and Ret Proto-Oncogene (RET)
    • Impact of Patent Expiries

Chapter 10: Competitive Landscape

  • Overview
  • Leading Companies
    • Roche
    • Novartis
    • Celgene
    • Bristol-Meyers Squibb
    • Johnson & Johnson
  • Recent Developments

Chapter 11: Company Profiles

  • ABBVIE, INC.
    • Company Overview
    • Financial Information
    • Products
    • Clinical Developments
  • AMGEN
    • Company Overview
    • Financial Information
    • Products
  • ARRAY BIOPHARMA INC.
    • Company Overview
    • Products
    • AstraZeneca plc
    • Company Overview
    • Financial Information
    • Key Developments
  • ASTELLAS PHARMA INC.
    • Company Overview
    • Products
  • BAYER HEALTHCARE
    • Company Overview
    • Products
  • BRISTOL-MYERS SQUIBB
    • Company Overview
    • Financial Information
    • Products
  • BIOGEN INC.
    • Company Overview
  • CELGENE CORP.
    • Company Overview
    • Financial Information
    • Products
  • CELLDEX THERAPEUTICS INC.
    • Company Overview
    • Products
  • GLAXOSMITHKLINE
    • Company Overview
  • GILEAD SCIENCES, INC.
    • Company Overview
    • Product
  • ELI LILLY AND CO.
    • Company Overview
    • Financial Information
    • Products
  • EISAI CO. LTD.
    • Company Overview
    • Products
  • F HOFFMAN-LA ROCHE LTD.
    • Company Overview
    • Financial Information
    • Products
    • Key Developments
  • IMMUNOCELLULAR THERAPEUTICS LTD.
    • Company Overview
    • Products
  • IMMUNOGEN INC.
    • Company Overview
  • INCYTE CORP.
    • Company Overview
  • INFINITY PHARMACEUTICALS, INC.
    • Company Overview
  • JOHNSON & JOHNSON
    • Company Overview
    • Financial Information
    • Products
  • MERCK & CO., INC.
    • Financial Information
    • Products
  • NOVARTIS AG
    • Company Overview
    • Financial Information
    • Products
    • Clinical Development
    • Key Developments
  • NEW LINK GENETICS CORP.
    • Company Overview
  • OTSUKA HOLDINGS CO. LTD.
    • Company Overview
  • PFIZER INC.
    • Company Overview
    • Financial Information
    • Key Developments
  • REGENERON PHARMACEUTICALS INC.
    • Company Overview
  • SANOFI SA
    • Company Overview
    • Financial Information
    • Products
    • Key Developments
  • SELLAS LIFE SCIENCES GROUP
    • Company Overview
  • TAKEDA PHARMACEUTICALS
    • Company Overview
  • VERASTEM INC.
    • Company Overview

Chapter 12: Appendix: Acronyms

Back to Top
전화 문의
F A Q
 
BCC Research